New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
08:18 EDTAZN, BCSAstraZeneca, Barclays investors push back on executive pay, Telegraph says
38.5% of AstraZeneca (AZN) shareholders voted against the company's executive pay plan, while 24% of investors voted against Barclays' (BCS) pay plan, reported The Telegraph. "We are disappointed with today's vote. As a priority we will be seeking to understand what concerns lay behind this," said an AstraZeneca spokesman. Reference Link
News For AZN;BCS From The Last 14 Days
Check below for free stories on AZN;BCS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
06:55 EDTBCSBarclays may reval GBP30B reduction in "bad bank," London Times reports
Barclays may reveal on Wednesday with its earnings report that it has reduced the size of its "bad bank" by as much as GBP30B, the London Times reports. Barclays previously said it looked to slash the size of the unit to about GBP80B by the end of the year. Reference Link
05:36 EDTAZNQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 25, 2014
06:40 EDTBCSLoan write down standards changed for non-U.S. banks, NY Times says
A new accounting rule will enable banks outside of the U.S. to write down the value of loans earlier but could cause loans to become less attractive for those banks, according to The New York Times. The rule was issued by the International Accounting Standards Board, whose guidelines are followed in more than 100 countries but not in America, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS).Reference Link
July 24, 2014
10:46 EDTBCSBarclays files motion to dismiss lawsuit over dark pool, NY Times reports
Barclays filed a motion to dismiss a lawsuit from the NY State attorney general that accused the bank of lying to customers on its private stock market, reports the New York Times. The bank said its customers were sophisticated enough to understand that "glossy marketing brochures" do not reflect its actual composition. Reference Link
July 22, 2014
07:31 EDTBCSSenate Homeland Security & Government Affairs Committee to hold a hearing
Subscribe for More Information
07:16 EDTBCSBarclays plunges from 2nd to 12th in U.S. dark pool ranks after suit, FT says
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
08:11 EDTBCSWarnings sounded over Barclays dark pool months before NY AG, WSJ says
Subscribe for More Information
July 18, 2014
11:21 EDTBCSBritish antitrust regulator to investigate country's banks, NY Times reports
The U.K.'s antitrust authorities said they expected to open a formal investigation into Britain's retail banking industry, reports the New York Times. The regulators cited barriers to competition that include control of a national network of branches by four large banks that control more than three-quarters of the market. Reference Link
July 16, 2014
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 14, 2014
07:13 EDTBCSDark pool investigation ups pressure on Barclays head, Reuters says
Barclays head Antony Jenkins is up one of biggest tests of his leadership when he chooses whether the firm should fight accusations that it deceived and defrauded U.S. clients, reported Reuters. If Jenkins accepts the allegations, he will have to deal with a problem arising from his promise to jettison any business that does not fit into the firm's new unblemished image. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use